Aquestive Therapeutics Inc. (NASDAQ: AQST) reported Q1 EPS of ($0.59), $0.09 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $11.59 million.

GUIDANCE:

Aquestive Therapeutics Inc. sees FY2019 revenue of $33-45 million, versus the consensus of $38.8 million.

• Non-GAAP gross margins of 70% to 72% on total revenues;
• Non-GAAP Adjusted EBITDA loss of $40 million to $45 million; and
• Cash burn of approximately $45 million to $50 million after considering interest, capital spending and working capital effects, but prior to any non-dilutive capital transactions.

For earnings history and earnings-related data on Aquestive Therapeutics Inc. (AQST) click here.